Role of microRNAs in kidney homeostasis and disease

Kidney International

Volumn 81, Issue 7, 2012, Pages 617-627

  Chandrasekaran, Karthikeyan ^a   Karolina, Dwi S ^a   Sepramaniam, Sugunavathi ^a   Armugam, Arunmozhiarasi ^a   Wintour, E Marelyn ^b   Bertram, John F ^b   Jeyaseelan, Kandiah ^a,b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b MONASH UNIVERSITY   (Australia)

Author keywords

aquaporin; blood pressure regulation; ion channel; microRNAs; nephron; renal disease

Indexed keywords

AQUAPORIN; AQUAPORIN 1; AQUAPORIN 11; AQUAPORIN 2; AQUAPORIN 3; AQUAPORIN 4; AQUAPORIN 6; AQUAPORIN 7; MESSENGER RNA; MICRORNA; OSMOTIC RESPONSE ELEMENT BINDING PROTEIN; SMAD PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN;

BIOGENESIS; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; ESSENTIAL HYPERTENSION; GENE; GENE MUTATION; GENE OVEREXPRESSION; HORMONAL REGULATION; HUMAN; KIDNEY CANCER; KIDNEY DEVELOPMENT; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; NEPHROGENIC DIABETES INSIPIDUS; NEPHROSCLEROSIS; NONHUMAN; OSMOTIC RESPONSE ELEMENT BINDING PROTEIN GENE; PATHOGENESIS; POLYCYSTIC KIDNEY AND HEPATIC DISEASE 1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RENOVASCULAR HYPERTENSION; REVIEW; RNA ANALYSIS; ZINC FINGER E BOX BINDING HOMEOBOX 2 GENE;

EID: 84858328459     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.448     Document Type: Review

References (193)

1. Bissinger RL. Renal physiology part 1: Structure and function. Neonatal Netw 1995; 14: 9-20.
2. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854.
3. Shcherbata HR, Hatfield S, Ward EJ et al. The microrna pathway plays a regulatory role in stem cell division. Cell Cycle 2006; 5: 172-175.
4. Shivdasani RA. MicroRNAs: Regulators of gene expression and cell differentiation. Blood 2006; 108: 3646-3653.
5. Esau C, Davis S, Murray SF et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87-98.
6. Rodriguez A, Griffiths-Jones S, Ashurst JL et al. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004; 14: 1902-1910.
7. Farh KK, Grimson A, Jan C et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 2005; 310: 1817-1821.
8. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006; 13: 1097-1101.
9. Kim VN. MicroRNA biogenesis: Coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005; 6: 376-385.
10. Gregory RI, Chendrimada TP, Cooch N et al. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005; 123: 631-640.
11. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003; 115: 209-216.
12. Valencia-Sanchez MA, Liu J, Hannon GJ et al. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006; 20: 515-524.
13. Li LC, Okino ST, Zhao H et al. Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA 2006; 103: 17337-17342.
14. Janowski BA, Younger ST, Hardy DB et al. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol 2007; 3: 166-173.
15. Place RF, Li LC, Pookot D et al. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA 2008; 105: 1608-1613.
16. Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNAmediated gene silencing. Cell 2008; 132: 9-14.
17. Fazi F, Nervi C. MicroRNA: Basic mechanisms and transcriptional regulatory networks for cell fate determination. Cardiovasc Res 2008; 79: 553-561.
18. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet 2008; 9: 102-114.
19. Makeyev EV, Maniatis T. Multilevel regulation of gene expression by microRNAs. Science 2008; 319: 1789-1790.
20. Chua JH, Armugam A, Jeyaseelan K. MicroRNAs: Biogenesis, function and applications. Curr Opin Mol Ther 2009; 11: 189-199.
21. Shomron N, Levy C. MicroRNA-biogenesis and pre-mRNA splicing crosstalk. J Biomed Biotechnol 2009; 2009: 1-6.
22. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597-610.
23. Davis-Dusenbery BN, Hata A. Mechanisms of control of microRNA biogenesis. J Biochem 2010; 148: 381-392.
24. Harvey SJ, Jarad G, Cunningham J et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol 2008; 19: 2150-2158.
25. Ho JJ, Marsden PA. Dicer cuts the kidney. J Am Soc Nephrol 2008; 19: 2043-2046.
26. Sun Y, Koo S, White N et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res 2004; 32: E188.
27. Tian Z, Greene AS, Pietrusz JL et al. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res 2008; 18: 404-411.
28. Agre P. The aquaporin water channels. Proc Am Thorac Soc 2006; 3: 5-13.
29. King LS, Agre P. Pathophysiology of the aquaporin water channels. Annu Rev Physiol 1996; 58: 619-648.
30. Jeyaseelan K, Sepramaniam S, Armugam A et al. Aquaporins: A promising target for drug development. Expert Opin Ther Targets 2006; 10: 889-909.
31. Pallone TL, Edwards A, Ma T et al. Requirement of aquaporin-1 for NaCldriven water transport across descending vasa recta. J Clin Invest 2000; 105: 215-222.
32. King LS, Choi M, Fernandez PC et al. Defective urinary-concentrating ability due to a complete deficiency of aquaporin-1. N Engl J Med 2001; 345: 175-179.
33. Fushimi K, Uchida S, Hara Y et al. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993; 361: 549-552.
34. Nielsen S, Digiovanni SR, Christensen EI et al. Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci USA 1993; 90: 11663-11667.
35. Nielsen S, Chou CL, Marples D et al. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA 1995; 92: 1013-1017.
36. Nonoguchi H, Owada A, Kobayashi N et al. Immunohistochemical localization of V2 vasopressin receptor along the nephron and functional role of luminal V2 receptor in terminal inner medullary collecting ducts. J Clin Invest 1995; 96: 1768-1778.
37. Loonen AJ, Knoers NV, van Os CH et al. Aquaporin 2 mutations in nephrogenic diabetes insipidus. Semin Nephrol 2008; 28: 252-265.
38. Savelkoul PJ, De Mattia F, Li Y et al. p.R254Q mutation in the aquaporin-2 water channel causing dominant nephrogenic diabetes insipidus is due to a lack of arginine vasopressin-induced phosphorylation. Hum Mutat 2009; 30: E891-E903.
39. Yang B, Gillespie A, Carlson EJ et al. Neonatal mortality in an aquaporin-2 knock-in mouse model of recessive nephrogenic diabetes insipidus. J Biol Chem 2001; 276: 2775-2779.
40. Asai T, Kuwahara M, Kurihara H et al. Pathogenesis of nephrogenic diabetes insipidus by aquaporin-2 C-terminus mutations. Kidney Int 2003; 64: 2-10.
41. Verkman AS. Aquaporins: Translating bench research to human disease. J Exp Biol 2009; 212: 1707-1715.
42. Frigeri A, Gropper MA, Turck CW et al. Immunolocalization of the mercurial-insensitive water channel and glycerol intrinsic protein in epithelial cell plasma membranes. Proc Natl Acad Sci USA 1995; 92: 4328-4331.
43. Kwon TH, Nielsen J, Masilamani S et al. Regulation of collecting duct AQP3 expression: Response to mineralocorticoid. Am J Physiol Renal Physiol 2002; 283: F1403-F1421.
44. Ma T, Song Y, Yang B et al. Nephrogenic diabetes insipidus in mice lacking aquaporin-3 water channels. Proc Natl Acad Sci USA 2000; 97: 4386-4391.
45. Van Hoek AN, Bouley R, Lu Y et al. Vasopressin-induced differential stimulation of AQP4 splice variants regulates the in-membrane assembly of orthogonal arrays. Am J Physiol Renal Physiol 2009; 296: F1396-F1404.
46. Chou CL, Ma T, Yang B et al. Fourfold reduction of water permeability in inner medullary collecting duct of aquaporin-4 knockout mice. Am J Physiol 1998; 274: C549-C554.
47. Yasui M, Kwon TH, Knepper MA et al. Aquaporin-6: An intracellular vesicle water channel protein in renal epithelia. Proc Natl Acad Sci USA 1999; 96: 5808-5813.
48. Ohshiro K, Yaoita E, Yoshida Y et al. Expression and immunolocalization of AQP6 in intercalated cells of the rat kidney collecting duct. Arch Histol Cytol 2001; 64: 329-338.
49. Nejsum LN, Elkjaer M, Hager H et al. Localization of aquaporin-7 in rat and mouse kidney using RT-PCR, immunoblotting, and immunocytochemistry. Biochem Biophys Res Commun 2000; 277: 164-170.
50. Rojek A, Praetorius J, Frokiaer J et al. A current view of the mammalian aquaglyceroporins. Annu Rev Physiol 2008; 70: 301-327.
51. Okada S, Misaka T, Tanaka Y et al. Aquaporin-11 knockout mice and polycystic kidney disease animals share a common mechanism of cyst formation. FASEB J 2008; 22: 3672-3684.
52. Morishita Y, Matsuzaki T, Hara-chikuma M et al. Disruption of aquaporin-11 produces polycystic kidneys following vacuolization of the proximal tubule. Mol Cell Biol 2005; 25: 7770-7779.
53. Tchekneva EE, Khuchua Z, Davis LS et al. Single amino acid substitution in aquaporin 11 causes renal failure. J Am Soc Nephrol 2008; 19: 1955-1964.
54. Sepramaniam S, Karolina DS, Armugam A et al. Micrornas: Potential applications in aquaporin associated pathogenesis. In: Mulligan JA (ed.) MicroRNA: Expression, Detection and Therapeutic Strategies. Nova Science Publishers, Inc, 2011 pp 1-32, Chapter 1.
55. Sepramaniam S, Armugam A, Lim KY et al. MicroRNA 320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia. J Biol Chem 2010; 285: 29223-29230.
56. Suzuki H, Saruta T. An overview of blood pressure regulation associated with the kidney. Contrib Nephrol 2004; 143: 1-15.
57. Jentsch TJ, Hubner CA, Fuhrmann JC. Ion channels: Function unravelled by dysfunction. Nat Cell Biol 2004; 6: 1039-1047.
58. Vallon V, Grahammer F, Volkl H et al. KCNQ1-dependent transport in renal and gastrointestinal epithelia. Proc Natl Acad Sci USA 2005; 102: 17864-17869.
59. Tremblay AM, Dufour CR, Ghahremani M et al. Physiological genomics identifies estrogen-related receptor alpha as a regulator of renal sodium and potassium homeostasis and the renin-angiotensin pathway. Mol Endocrinol 2010; 24: 22-32.
60. Cohen DM. TRPV4 and the mammalian kidney. Pflugers Arch 2005; 451: 168-175.
61. Hoenderop JG, van Leeuwen JP, van der Eerden BC et al. Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 2003; 112: 1906-1914.
62. Voets T, Nilius B, Hoefs S et al. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem 2004; 279: 19-25.
63. Elizondo MR, Budi EH, Parichy DM. trpm7 regulation of in vivo cation homeostasis and kidney function involves stanniocalcin 1 and fgf23. Endocrinology 2010; 151: 5700-5709.
64. Hou J, Renigunta A, Gomes AS et al. Claudin-16 and claudin-19 interaction is required for their assembly into tight junctions and for renal reabsorption of magnesium. Proc Natl Acad Sci USA 2009; 106: 15350-15355.
65. Tsukaguchi H, Shayakul C, Berger UV et al. Urea transporters in kidney: Molecular analysis and contribution to the urinary concentrating process1. Am J Physiol 1998; 275: F319-F324.
66. Flynt AS, Thatcher EJ, Burkewitz K et al. miR-8 microRNAs regulate the response to osmotic stress in zebrafish embryos. J Cell Biol 2009; 185: 115-127.
67. Huang W, Liu H, Wang T et al. Tonicity-responsive microRNAs contribute to the maximal induction of osmoregulatory transcription factor OREBP in response to high-NaCl hypertonicity. Nucleic Acids Res 2011; 39: 475-485.
68. Levens NR, Freedlender AE, Peach MJ et al. Control of renal function by intrarenal angiotensin II. Endocrinology 1983; 112: 43-49.
69. Levens NR, Peach MJ, Carey RM. Role of the intrarenal renin-angiotensin system in the control of renal function. Circ Res 1981; 48: 157-167.
70. Carey RM, Siragy HM. Newly recognized components of the reninangiotensin system: Potential roles in cardiovascular and renal regulation. Endocr Rev 2003; 24: 261-271.
71. Gomez RA, Lynch KR, Chevalier RL et al. Renin and angiotensinogen gene expression in maturing rat kidney. Am J Physiol 1988; 254: F582-F587.
72. Ingelfinger JR, Zuo WM, Fon EA et al. In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest 1990; 85: 417-423.
73. Yanagawa N, Capparelli AW, Jo OD et al. Production of angiotensinogen and renin-like activity by rabbit proximal tubular cells in culture. Kidney Int 1991; 39: 938-941.
74. Bruneval P, Hinglais N, Alhenc-Gelas F et al. Angiotensin I converting enzyme in human intestine and kidney. Ultrastructural immunohistochemical localization. Histochemistry 1986; 85: 73-80.
75. Moe OW, Ujiie K, Star RA et al. Renin expression in renal proximal tubule. J Clin Invest 1993; 91: 774-779.
76. Peach MJ. Renin-angiotensin system: Biochemistry and mechanisms of action. Physiol Rev 1977; 57: 313-370.
77. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the reninangiotensin system. Circulation 1993; 87: 1816-1828.
78. Sequeira-Lopez ML, Weatherford ET, Borges GR et al. The microRNAprocessing enzyme dicer maintains juxtaglomerular cells. J Am Soc Nephrol 2010; 21: 460-467.
79. Hsueh WA, Baxter JD. Human prorenin. Hypertension 1991; 17: 469-477.
80. Soubrier F, Wei L, Hubert C et al. Molecular biology of the angiotensin I converting enzyme: II. Structure-function. Gene polymorphism and clinical implications. J Hypertens 1993; 11: 599-604.
81. Sibony M, Gasc JM, Soubrier F et al. Gene expression and tissue localization of the two isoforms of angiotensin I converting enzyme. Hypertension 1993; 21: 827-835.
82. Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab 2003; 88: 2364-2372.
83. Karolina DS, Wintour EM, Bertram J et al. Riboregulators in kidney development and function. Biochimie 2010; 92: 217-225.
84. Larsson SH, Aperia A. Renal growth in infancy and childhood experimentalstudies of regulatory mechanisms. Pediatr Nephrol 1991; 5: 439-442.
85. Landgraf P, Rusu M, Sheridan R et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129: 1401-1414.
86. Sun Y, Koo S, White N et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acid Res 2004; 32: E188.
87. Baskerville S, Bartel DP. Microarray profiling of microRNAs revel as frequent coexpression with neighbouring miRNAs and host genes. RNA 2005; 11: 241-247.
88. Nagalakshmi VK, Ren Q, Pugh MM et al. Dicer regulates the development of nephrogenic and ureteric compartments in the mammalian kidney. Kidney Int 2011; 79: 317-330.
89. Ho J, Pandey P, Schatton T et al. The pro-apoptotic protein Bim is a MicroRNA target in kidney progenitors. J Am Soc Nephrol 2011; 22: 1053-1063.
90. Bai XY, Ma Y, Ding R et al. miR-335 and miR-34a promote renal senescence by suppressing mitochondrial antioxidative enzymes. J Am Soc Nephrol 2011; 220: 1252-1261.
91. Ho J, Ng KH, Rosen S et al. Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol 2008; 19: 2069-2075.
92. Shi S, Yu L, Chiu C et al. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol 2008; 19: 2159-2169.
93. Zhdanova O, Srivastava S, Di L et al. The inducible deletion of Drosha and microRNAs in mature podocytes results in a collapsing glomerulopathy. Kidney Int 2011; 80: 719-730.
94. Gallagher AR, Germino GG, Somlo S. Molecular advances in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010; 17: 118-130.
95. Torres VE, Harris PC. Mechanisms of disease: Autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2006; 2: 40-55; quiz 55.
96. Ibraghimov-Beskrovnaya O, Bukanov N. Polycystic kidney diseases: From molecular discoveries to targeted therapeutic strategies. Cell Mol Life Sci 2008; 65: 605-619.
97. Chang MY, Ong AC. Autosomal dominant polycystic kidney disease: Recent advances in pathogenesis and treatment. Nephron Physiol 2008; 108: P1-p7.
98. Onuchic LF, Furu L, Nagasawa Y et al. PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet 2002; 70: 1305-1317.
99. Ward CJ, Hogan MC, Rossetti S et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 2002; 30: 259-269.
100. Tan YC, Blumenfeld J, Rennert H. Autosomal dominant polycystic kidney disease: Genetics, mutations and microRNAs. Biochim Biophys Acta 2011; 1812: 1202-1212.
101. Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: Early occurrence and unique aspects. J Am Soc Nephrol 2001; 12: 194-200.
102. Cadnapaphornchai M, McFann M, Strain J et al. Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 2009; 4: 820-829.
103. Gabow PA, Chapman AB, Johnson AM et al. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1990; 38: 1177-1180.
104. Chapman AB, Johnson AM, Rainquet S et al. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997; 8: 1292-1297.
105. Pandey P, Brors B, Srivastava PK et al. Microarray-based approach identifies microRNAs and their target functional patterns in polycystic kidney disease. BMC Genomics 2008; 9: 624.
106. Sun H, Li QW, Lv XY et al. MicroRNA-17 post-transcriptionally regulates polycystic kidney disease-2 gene and promotes cell proliferation. Mol Biol Rep 2010; 37: 2951-2958.
107. Tran U, Zakin L, Schweickert A et al. The RNA-binding protein bicaudal C regulates polycystin 2 in the kidney by antagonizing miR-17 activity. Development 2010; 137: 1107-1116.
108. Tran U, Pickney LM, Ozpolat BD et al. Xenopus Bicaudal-C is required for the differentiation of the amphibian pronephros. Dev Biol 2007; 307: 152-164.
109. Pandey P, Qin S, Ho J et al. Systems biology approach to identify transcriptome reprogramming and candidate microRNA targets during the progression of polycystic kidney disease. BMC Syst Biol 2011; 5: 56.
110. Lee SO, Masyuk T, Splinter P et al. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest 2008; 118: 3714-3724.
111. Kristjansdottir K, Rudolph J. Cdc25 phosphatases and cancer. Chem Biol 2004; 11: 1043-1051.
112. Krolewski AS, Canessa M, Warram JH et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 140-145.
113. Harkonen S, Kjellstrand CM. Exacerbation of diabetic renal failure following intravenous pyelography. Am J Med 1977; 63: 939-946.
114. Andersen AR, Christiansen JS, Andersen JK et al. Diabetic nephropathy in Type 1 (insulin dependent) diabetes: An epidemiological study. Diabetologia 1983; 25: 496-501.
115. Ballard DJ, Humphrey LL, Melton 3rd LJ et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 1988; 37: 405-412.
116. Chowdhury TA, Dyer PH, Kumar S et al. Genetic determinants of diabetic nephropathy. Clin Sci (Lond) 1999; 96: 221-230.
117. Dalla Vestra M, Saller A, Bortoloso E et al. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 2000; 26(Suppl 4): S8-S14.
118. Hasslacher C, Bostedt-Kiesel A, Kempe HP et al. Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 1051-1056.
119. Mogensen CE. Systemic blood pressure and glomerular leakage with particular reference to diabetes and hypertension. J Intern Med 1994; 235: 297-316.
120. Microalbuminuria Collaborative Study Group, UK. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: A cohort study. BMJ 1993; 306: 1235-1239.
121. Lorenzen JM, Haller H, Thum T. MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol 2011; 7: 286-294.
122. Kato M, Zhang J, Wang M et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA 2007; 104: 3432-3437.
123. Kasinath BS, Feliers D. The complex world of kidney microRNAs. Kidney Int 2011; 80: 334-337.
124. Kato M, Arce L, Wang M et al. A microRNA circuit mediates transforming growth factor-b1 autoregulation in renal glomerular mesangial cells. Kidney Int 2011; 80: 358-368.
125. Krupa A, Jenkins R, Luo DD et al. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 2010; 21: 438-447.
126. Kato M, Putta S, Wang M et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009; 11: 881-889.
127. Wang Q, Wang Y, Minto AW et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 2008; 22: 4126-4135.
128. Zhang Z, Peng H, Chen J et al. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett 2009; 583: 2009-2014.
129. Du B, Ma LM, Huang MB et al. High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett 2010; 584: 811-816.
130. Long J, Wang Y, Wang W et al. MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem 2011; 286: 11837-11848.
131. Long J, Wang Y, Wang W et al. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem 2010; 285: 23457-23465.
132. Gottardo F, Liu CG, Ferracin M et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007; 25: 387-392.
133. White NM, Yousef GM. MicroRNAs: Exploring a new dimension in the pathogenesis of kidney cancer. BMC Med 2010; 8: 65.
134. Yi Z, Fu Y, Zhao S et al. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J Cancer Res Clin Oncol 2010; 136: 855-862.
135. Youssef YM, White NM, Grigull J et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 2011; 59: 721-730.
136. van Spronsen DJ, Mulders PF, De Mulder PH. Novel treatments for metastatic renal cell carcinoma. Crit Rev Oncol Hematol 2005; 55: 177-191.
137. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-875.
138. Jung M, Mollenkopf HJ, Grimm C et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 2009; 13: 3918-3928.
139. Juan D, Alexe G, Antes T et al. Identification of a microRNA panel for clear-cell kidney cancer. Urology 2010; 75: 835-841.
140. Weng L, Wu X, Gao H et al. MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol 2010; 222: 41-51.
141. Petillo D, Kort EJ, Anema J et al. MicroRNA profiling of human kidney cancer subtypes. Int J Oncol 2009; 35: 109-114.
142. Lorenzen JM, Kielstein JT, Hafer C et al. Circulating miR-210 predicts survival in critically Ill patients with acute kidney injury. Clin J Am Soc Nephrol 2011; 6: 1540-1546.
143. Catto JW, Alcaraz A, Bjartell AS et al. MicroRNA in prostate,bladder, and kidney cancer: A systematic review. Eur Urol 2011; 59: 671-681.
144. Redova M, Svoboda M, Slaby O. MicroRNAs and their target gene networks in renal cell carcinoma. Biochem Biophys Res Commun 2011; 405: 153-156.
145. White NM, Bao TT, Grigull J et al. miRNA profiling for clear cell renal cell carcinoma: Biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol 2011; 186: 1077-1083.
146. Lodygin D, Tarasov V, Epanchintsev A et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591-2600.
147. Vogt M, Munding J, Gruner M et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch 2011; 458: 313-322.
148. Nakada C, Matsuura K, Tsukamoto Y et al. Genome-wide microRNA expression profiling in renal cell carcinoma: Significant down-regulation of miR-141 and miR-200c. J Pathol 2008; 216: 418-427.
149. Takamizawa J, Konishi H, Yanagisawa K et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-3756.
150. Kort EJ, Farber L, Tretiakova M et al. The E2F3-Oncomir-1 axis is activated in Wilms' tumor. Cancer Res 2008; 68: 4034-4038.
151. Drake KM, Ruteshouser EC, Natrajan R et al. Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: Putative role for miR-562. Clin Cancer Res 2009; 15: 5985-5992.
152. Veronese A, Lupini L, Consiglio J et al. Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res 2010; 70: 3140-3149.
153. Chow TF, Mankaruos M, Scorilas A et al. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol 2010; 183: 743-751.
154. Fenner A. RCC classification using miRNA signatures. Nat Rev Urol 2011; 8: 120.
155. Fridman E, Dotan Z, Barshack I et al. Accurate molecular classification of renal tumors using microRNA expression. J Mol Diagn 2010; 12: 687-696.
156. Freedman BI, Iskandar SS, Appel RG. The link between hypertension and nephrosclerosis. Am J Kidney Dis 1995; 25: 207-221.
157. Bleyer AJ, Appel RG. Risk factors associated with hypertensive nephrosclerosis. Nephron 1999; 82: 193-198.
158. Weisstuch JM, Dworkin LD. Does essential hypertension cause end-stage renal disease? Kidney Int Suppl 1992; 36: S33-S37.
159. Luke RG. Essential hypertension: A renal disease? A review and update of the evidence. Hypertension 1993; 21: 380-390.
160. Luft FC. Hypertensive nephrosclerosis: Update. Curr Opin Nephrol Hypertens 2004; 13: 147-154.
161. Wang G, Kwan BC, Lai FM et al. Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. Am J Hypertens 2010; 23: 78-84.
162. Liu Y, Taylor NE, Lu L et al. Renal medullary microRNAs in Dahl saltsensitive rats: MiR-29b regulates several collagens and related genes. Hypertension 2010; 55: 974-982.
163. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens 1988; 1: 335-347.
164. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: A paradigm shift in nephrology. Kidney Int 1996; 49: 1774-1777.
165. Brenner BM, Mackenzie HS. Nephron mass as a risk factor for progression of renal disease. Kidney Int Suppl 1997; 63: S124-S127.
166. Hoy WE, Hughson MD, Singh GR et al. Reduced nephron number and glomerulomegaly in Australian Aborigines: A group at high risk for renal disease and hypertension. Kidney Int 2006; 70: 104-110.
167. Hoy WE, Bertram JF, Denton RD et al. Nephron number, glomerular volume, renal disease and hypertension. Curr Opin Nephrol Hypertens 2008; 17: 258-265.
168. Puelles VG, Hoy WE, Hughson MD et al. Glomerular number and size variability and risk for kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 7-15.
169. Hoy WE, Douglas-Denton RN, Hughson MD et al. A stereological study of glomerular number and volume: Preliminary findings in a multiracial study of kidneys at autopsy. Kidney Int Suppl 2003; 63: S31-S37.
170. Hughson M, Farris 3rd AB, Douglas-Denton R et al. Glomerular number and size in autopsy kidneys: The relationship to birth weight. Kidney Int 2003; 63: 2113-2122.
171. Samuel T, Hoy WE, Douglas-Denton R et al. Determinants of glomerular volume in different cortical zones of the human kidney. J Am Soc Nephrol 2005; 16: 3102-3109.
172. Keller G, Zimmer G, Mall G et al. Nephron number in patients with primary hypertension. N Engl J Med 2003; 348: 101-108.
173. Martin MM, Lee EJ, Buckenberger JA et al. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 2006; 281: 18277-18284.
174. Sethupathy P, Borel C, Gagnebin M et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 30 untranslated region: A mechanism for functional singlenucleotide polymorphisms related to phenotypes. Am J Hum Genet 2007; 81: 405-413.
175. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-1784.
176. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12.
177. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
178. Burns WC, Kantharidis P, Thomas MC. The role of tubular epithelialmesenchymal transition in progressive kidney disease. Cells Tissues Organs 2007; 185: 222-231.
179. Neilson EG. Mechanisms of disease: Fibroblasts-a new look at an old problem. Nat Clin Pract Nephrol 2006; 2: 101-108.
180. Wu Y, Zhou BP. New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 643-650.
181. Gregory PA, Bert AG, Paterson EL et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
182. Korpal M, Lee ES, Hu G et al. The miR-200 family inhibits epithelialmesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-14914.
183. Park SM, Gaur AB, Lengyel E et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
184. Oba S, Kumano S, Suzuki E et al. miR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS One 2010; 5: E13614.
185. Wang B, Koh P, Winbanks C et al. miR-200a Prevents renal fibrogenesis through repression of TGF-beta2 expression. Diabetes 2011; 60: 280-287.
186. Wang B, Herman-Edelstein M, Koh P et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010; 59: 1794-1802.
187. Kriegel AJ, Fang Y, Liu Y et al. MicroRNA-target pairs in human renal epithelial cells treated with transforming growth factor beta 1: A novel role of miR-382. Nucleic Acids Res 2010; 38: 8338-8347.
188. Qin W, Chung AC, Huang XR et al. TGF-{beta}/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 2011; 22: 1462-1474.
189. Chung AC, Huang XR, Meng X et al. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol 2010; 21: 1317-1325.
190. Dai Y, Sui W, Lan H et al. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int 2009; 29: 749-754.
191. Te JL, Dozmorov IM, Guthridge JM et al. Identification of unique microRNA signature associated with lupus nephritis. PLoS One 2010; 5: E10344.
192. Wang G, Kwan BC, Lai FM et al. Intrarenal expression of microRNAs in patients with IgA nephropathy. Lab Invest 2010; 90: 98-103.
193. Wang G, Kwan BC, Lai FM et al. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis Markers 2010; 28: 79-86.